



DECLARATION OF CONFORMITY

Manufacturer: **Invivoscribe, Inc.**
10222 Barnes Canyon Rd. Bldg 1
San Diego, California 92121
United States of America

Authorized Representative: **Invivoscribe Technologies, SARL**
327 Boulevard Michelet
13009 Marseille
FRANCE
Phone: +33 (0)4 42 01 78 10
Fax : +33 (0)4 88 56 22 89


Family Name: LeukoStrat®

Device Trade Name: **FLT3 Mutation Assay**

Catalog #	Device	Quantity	Basic UDI-DI	GTIN	EMDN Code
K4120291	LeukoStrat® CDx FLT3 Mutation Assay	33 Tests	081002273K41202914S	00850052003715	W01060299

I, the undersigned, hereby declare that the *in-vitro* diagnostic medical devices specified above conform to the European Directive 98/79/EC, *In vitro* Diagnostic Medical Device Directive, Annex III.

*Date of Validity: 25 Jan 2023

By: 

Jason Gerhold
Global Director of Quality, Regulatory and Clinical Affairs
Invivoscribe, Inc.
10222 Barnes Canyon Rd. Bldg 1
San Diego, California 92121
USA

*Originally signed on 05/18/2022, no significant changes have occurred to the product since that date